Untapped Endometriosis Market SLBST Pharma is pursuing a non-hormonal, immunomodulator-based therapy for endometriosis with FDA Phase 2 dose-finding approval. This positions them to capture patients who are dissatisfied with current options and may create demand for partnerships, co-development, or licensing of their reformulated HCQ approach.

Innovation and IP The company holds issued and pending patents protecting the novel indication, offering a defensible position for collaborations, exclusive licensing, or strategic manufacturing agreements around the endometriosis therapy and its immunomodulatory mechanism.

Evidence-backed Opportunity With a large addressable population (over 4 million diagnosed with endometriosis) and significant functional impairment, there is potential for payer conversations, compassionate use programs, and early access partnerships to accelerate market entry and adoption upon successful Phase 2 results.

Strategic Partnerships The early FDA Phase 2 readiness and a known, safer immunomodulator offer avenues for partnerships with larger biotech or pharma players seeking to expand non-hormonal pain therapies, as well as contract research organizations and manufacturing partners to support scale.

Tech and Digital Readiness SLBST Pharma’s tech stack and digital presence indicate capabilities for agile marketing, patient engagement, and digital trial recruitment. This enables scalable co-promotion, digital patient support programs, and streamlined outreach to clinicians and research networks for faster trial enrollment.